The Venture Codex

Participated · Series A · Apr 2026

Belo builds a mobile financial application that lets users hold and manage local fiat currencies alongside digital dollars within a single account. The platform automates foreign exchange transactions, peer-to-peer transfers, and international remittances, leveraging stablecoin infrastructure to reduce currency volatility and cross-border fees. The company is led by CEO Manuel Beaudroit and is headquartered in Buenos Aires. Belo has grown its user base to more than 3 million customers across the region. Following the $14 million Series A, the company is executing an international growth plan to enter Mexico, Chile, Colombia, Peru, Bolivia, and Paraguay. The new capital will also be used to scale engineering capacity and expand its operational footprint across Latin America.

Participated · Series A · Feb 2026

Founded in 2022, Sidekick offers a modern wealth-management platform aimed at professionals whose financial needs have outgrown entry-level investing apps. The service combines low-cost public-market investing, customised portfolios, private-market opportunities and Lombard loans secured against customers’ portfolios—products historically reserved for private banks. Sidekick’s managed strategies include offerings such as the All Weather portfolio, while its Multi Shield Savings product spreads cash across multiple partner banks to maximise FSCS protection. The company claims to manage more than £145 million in customer assets, underscoring demand for greater transparency and control among affluent professionals. Fees are presented transparently and clients receive guidance from in-house financial experts. With fresh capital, Sidekick plans to scale its product suite, grow headcount and expand operations in Cardiff while continuing to build out its technology platform.

Participated · Series A · Nov 2025

Founded in 2020, Devengo builds payment infrastructure that connects directly to Iberpay, allowing companies to initiate automatic, programmable and real-time euro transfers without relying on traditional banking intermediaries. Its API-centric platform targets multi-sector clients that need faster, lower-cost payment workflows and greater operational control. By eliminating a banking middle layer, Devengo claims advantages in speed, security and scalability. The company is positioning itself to capitalise on the EU Instant Payments Regulation and plans to expand its coverage across the entire Single European Payments Area. Looking ahead, management intends to add emerging protocols such as Request to Pay and instant international transfers to stay ahead of regulatory and technological shifts. Although no revenue or user figures were disclosed, the firm highlights strong backing from strategic investors including Spanish banks and telecom-linked venture arms, signalling traction within the local financial ecosystem.

Led · Seed · Jun 2024

Spike offers white‑labeled SDKs and non‑diagnostic RAG (retrieval‑augmented generation) AI products that let healthcare and digital‑health businesses add compliant, easy‑to‑implement AI features. Its platform aggregates high‑quality biomarkers from around 300 sources via a health data API, which feeds personalized co‑pilot applications such as trainer, dietitian, nurse, and physician assistants. The company emphasizes reducing LLM hallucinations and meeting strict regulatory requirements for sensitive health data while lowering time‑to‑market and engineering costs for customers. Spike’s customer roster includes Seguros SURA, Longevo, FITTR, EMMA, Moody Month and Pulsetto, and the startup is part of NVIDIA’s Inception Program for GenAI companies. The recently closed funding will be used to fuel continued growth and product expansion across healthcare and health‑tech verticals. The team includes co‑founders Povilas Gudzius and Nikita Pajanok and a broader group of technical hires supporting product and go‑to‑market efforts. Spike is a Palo Alto, CA–based B2B data technology and artificial intelligence startup that provides API aggregation, data pipeline management (ETL), and an AI-backed solution for wearables and IoT devices. The platform imports biometric metrics — including heart rate variability, glucose, cortisol, calories, sleep depth, and blood pressure — directly into clients' cloud via a managed ETL service. Spike supports commercially used optical, electrical, electrochemical, and electromechanical sensor types and serves clients in digital health, professional fitness, insurance, and automation. Led by CEO Povilas Gudzius, the company offers AI tools for health-related prediction, recommendation, and prevention. Spike raised $700K in a Pre-Seed funding round led by Geek Ventures, with participation from CEAS Investments and APX. The company intends to use the funds to accelerate growth, expand operations, and broaden its business reach.

Participated · Series A · Mar 2024

Tiny Health offers the first at-home gut microbiome test developed for babies, using shotgun metagenomics sequencing to detect over 120,000 bacteria, fungi, viruses, archaea and parasites and deliver individualized, evidence-based recommendations. The company has expanded its suite to serve adults, children (ages 3–17), vaginal testing for expectant mothers, and a B2B platform (Powered by Tiny) for clinical and partner integrations. Tiny Health has helped more than 25,000 families and reports 25% month-over-month growth since its 2022 launch. It recently added probiotic strain-tracking capabilities to show potential colonization of probiotic strains in the gut and vaginal microbiomes. The company conducts IRB-approved clinical studies focused on maternal-infant outcomes and aims to address pediatric chronic conditions linked to early-life gut imbalances. The new funding will support platform expansion across pediatrics, women’s health, metabolic and adult chronic conditions while continuing evidence-based microbiome research and partnerships. Tiny Health is a science-based platform focused on preventing gut imbalances in babies during the critical first 1,000 days that can lead to eczema, allergies, asthma, obesity, and other chronic diseases. Its core product, the Gut Health Test, is the first to use shotgun metagenomics sequencing tailored specifically for people trying to conceive, expecting mothers, and babies aged 0–3 years. The company processes tests in a CLIA-certified lab and uses shotgun metagenomics to deliver strain-level precision and a comprehensive profile of bacteria, fungi, parasites, viruses, and archaea. Every report includes a personalized review by a team of microbiome experts and evidence-based recommendations to help parents improve their children's gut health and optimize family health. Tiny's team includes microbiologists, physicians, bioinformaticians, and entrepreneurs with backgrounds at Mayo Clinic, UCSF, Harvard Medical, Johns Hopkins, Stanford, Cornell, and WashU. The company secured $4.5M in funding.